SpainSpain

Digna Biotech regains rights for inhibitor for systemic skin sclerosis

15.11.2011

Madrid/Barcelona – It was a rare example of a partnership between the two competing regions of Castile and Catalonia. Now the alliance between Digna Biotech and ISDIN has come to an end. Digna Biotech announced that it has reached an agreement with ISDIN to regain full rights to Disitertide peptide’s (P144) topical formulation for the therapy of skin conditions. Disitertide is a TGF-β1 (Transforming Growth Factor-Beta 1) inhibitor that has completed a Phase IIa trial for topical treatment of skin systemic sclerosis. “We will run this trial while also validating a primary end-point for a topical treatment on the disease as there is no one at present", said Digna's CEO Pablo Ortiz. In 2005 and 2006, EMA and FDA already had granted Disitertide (P144) Orphan Drug Designation to treat systemic sclerosis and localised scleroderma. Systemic sclerosis or scleroderma is a multi-systemic disorder characterised by the excessive synthesis and deposition of extracellular matrix proteins that leads to the fibrosis of skin and visceral organs. Digna Biotech is a University of Navarra’s spin-off biotech company funded by a group of investors representing some of the major corporations and financial institutions in Spain. It has its headquarters in Madrid.

SpainSpain

08.03.2012

Granada-based Integromics S.L. has teamed up with the Galician Foundation of Genomic Medicine (FPGMX) in Santiago de Compostela to secure a €1m EU grant from the European Regional Development Fund and the Spanish government. With...

SpainSpain

08.03.2012

Oryzon Genomics S.A (Barcelona) is entering preclinical testing with a first-in-class bispecific LSD1/MAO-B inhibitor. In addition to the classic target MAO-B, the drug also blocks histone demethylase LSD1, an epigenetic histone...

SpainSpain

06.03.2012

Granada-based nLife Therapeutics S.L. has raised €5m in total from two venture capitalists. Through Caixa Capital Risc and Caixa Capital Biomed, La Caixa invested €2.5m. The same amount has been placed by Invercaria via its...

SpainSpain

05.03.2012

Ordesa Laboratories has filed a patent for a novel Bifidobacterium strain isolated from infant feces. It has the capacity to combat rotavirus, says a study (Appl. Environ. Microbiol., doi:10.1128/AEM.05548).

SpainSpain

19.12.2011

Madrid – Researchers from Spain and the US have discovered an Ebola-like filovirus in bats in northern Spain. The first known filovirus native to Europe was reported in a study published in the journal PLOS Pathogens...

SpainSpain

15.12.2011

Barcelona - South western Europe gets a new R&D unit in the field of biomolecules. Kymos Pharma, a contract researcher based in Barcelona, has signed an agreement with the French biotechnology group Ipsen to create a R&D group...

SpainSpain

12.12.2011

Barcelona/Saffron Walden – Almirall S.A. and BioFocus announced that they have entered into a collaboration agreement to identify new compounds against key targets in projects aimed at the treatment of respiratory and...

SpainSpain

03.12.2011

Madrid/Abu Dhabi – Spanish biotechs are seeking collaborations with firms in the United Arab Emirates. At the end of November, Grupo Zeltia and 14 other Spanish companies presented their research at the forum “Innovation,...

SpainSpain

01.10.2011

Madrid – The Spanish Minister of Innovation and Science Cristina Garmendia has responded to reports about Roche’s­ delivery stop in Greece and pessimistic expectations for Spain. In Sept­ember, she stressed that the atmosphere...

SpainSpain

01.10.2011

Granada – Alentia Biotech, a joint venture of Grupo Ferrer Internacional S.A. and Laboratorios Farmacéuticos Rovi S.A, has announced plans to construct a national production centre to supply the Spanish population with flu...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-spain/article/digna-biotech-regains-rights-for-inhibitor-for-systemic-skin-sclerosis.html

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SILENCE THERAPEUTICS (UK)244.75 GBP4.15%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • ADDEX (CH)4.54 CHF108.3%
  • CELLECTIS (F)13.54 EUR103.6%

FLOP

  • THROMBOGENICS (B)8.51 EUR-52.2%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 11.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events